- Tiziana Life Sciences has widened its FY pretax loss to £8.6m, from £3.4m. Research and development costs weighed in at £6.3m, from £0.8m.

Chair Gabriele Cerrone said 2015 was an important year for Tiziana as the company continued to build and strengthen its portfolio of therapeutics to treat patients with significant unmet medical needs.

"We are focusing on two distinct disease areas: rare cancers and difficult to treat autoimmune diseases; and the addition of milciclib to our portfolio, as well as the acquisition of foralumab at the end of 2014, gives the Company two phase II candidates.

"We also remain on-track to progress our lead candidate in our Bcl-3 programme into the clinic in late 2016 or early 2017.

"The funds raised throughout the year demonstrate the confidence our shareholders have in Tiziana and we look forward to generating further shareholder value going forward."

Story provided by